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Carbapenems: do they have a future?
The pivotal role of glycopeptides in the
control of meticillin-resistant Staphyl-
ococcus aureus is well known and the
notoriety of this organism has ensured
that new antibacterial treatments have
been developed. Far less publicized is the
crisis in the treatment of Gram-negative
infections, especially those that are hos-
pital-acquired. In many cases, particularly
because of the emergence and spread of
extended-spectrum b-lactamases (ESBLs)
in the Enterobacteriaceae and the increased
isolation of non-fermenting bacteria, such
as Pseudomonas aeruginosa and Acineto-
bacter baumannii, the remaining standard
treatment option has been a group of
penem antibiotics with a carbon atom in
the side ring rather than the traditional
sulphur. These are the carbapenems.
In the UK, there are three main carbape-
nems, imipenem, meropenem and ertape-
nem, and a new addition, doripenem.
Imipenem is a broad-spectrum antibiotic,
derived from a compound isolated from
the soil bacterium Streptomyces cattleya
(Kahan et al., 1983), which has to be co-
administered with cilastatin to prevent its
degradation by the kidney. Mero-
penem is also a broad-spectrum b-lactam,
and has a therapeutic advantage over
imipenem because it can be used to treat
central nervous system infections. The
addition of a methyl group in the 1-position
of the carbapenem moiety in meropenem
makes it structurally different from imipe-
nem (Wiseman et al., 1995) and this
modification enhances the in vivo stability
of meropenem, compared to imipenem, and
it does not need to be co-administered with
cilastin (Edwards, 1995). Both compounds
are used as empiric therapy for a wide
range of severe Gram-negative infections.
Ertapenem has a more limited spectrum and
has largely been recommended for the
treatment of community-acquired infections,
especially those caused by bacteria carrying
an ESBL. It can partially inhibit non-
fermenting bacteria and thus would select
those strains that have a pre-disposition to
carbapenem resistance (Amyes et al., 2007).
This reason questions its use in the treatment
of hospital-acquired infections as it may
preferentially select non-fermenting bacteria.
Doripenem has a profile similar to that
of imipenem and meropenem and does
not overcome the majority of currently
prevalent mechanisms of resistance to the
carbapenems.
Mechanism of resistance
Unfortunately, resistance has emerged in
many bacteria treated with carbapenems.
The most common mechanisms of resist-
ance are the acquisition of carbapenem-
hydrolysing b-lactamases of Ambler class
D enzymes (oxacillinases) (CDO) (Poirel
& Nordmann, 2002), b-lactamases belong-
ing to class B (metallo-enzymes) (MBLs)
(Walsh et al., 2005) and a few class A
b-lactamases such as the KPC enzymes in
Klebsiella species. Often these b-lactamases
do not act alone and are often accompan-
ied by mutations in genes encoding
penicillin-binding proteins and alteration
in outer-membrane permeability; for
example, the loss of porins CarO and
Omp33–36 in A. baumannii (Gehrlein
et al., 1991).
In A. baumannii, the spread of carbapenem
resistance largely results from the clonal
dissemination of a resistant strain where a
crucial combination of a mobile carbape-
nem resistance gene (often encoding the
class D b-lactamases OXA-23 or OXA-58)
has entered a congenial host (Brown &
Amyes, 2006). The spread of these resistant
bacteria is due as much to cross-infection as
to antibiotic usage. These genes have
migrated to the congenial host because they
are closely linked to insertion sequences,
which have promoted their mobility
(Turton et al., 2006; Poirel & Nordmann,
2006). A further complication is that all
A. baumannii possess an inherent class D
b-lactamase, collectively known as OXA-
51-like, which can provide weak hydrolytic
activity on the carbapenems, though
currently only rarely produces clinical
resistance.
There are five groups of acquired MBLs
(IMP-like, VIM-like, SIM-1, SPM-1 and
GIM-1 enzymes). These have largely been
found in non-fermenting bacteria; for
instance the first three have been identified
in A. baumannii (Peleg et al., 2008). They
are less common in other Gram-negative
bacteria. Recent concern has focussed on
the emergence of resistance in the
Enterobacteriaceae, particularly with the
emergence of the NDM-1 b-lactamase in
Klebsiella species. Coupled with the emer-
gence of the KPC class A serine
b-lactamases, this augurs badly for the
carbapenems (Kumarasamy et al., 2010).
Unlike A. baumannii, the development and
spread of resistance in Klebsiella species is
less well defined and currently much rarer;
the emergence of the mobile b-lactamase
genes is still in its infancy and the crucial
combination of this gene in a suitable host
does not yet appear to have occurred. Thus
the mobile genes are still migrating and
this would be aided by imprudent therapy.
The importation of carbapenem-hydrolysing
b-lactamases is not the only threat in
Klebsiella species. ESBL-producing Kleb-
siella pneumoniae strains are now very
common and the carbapenems are often
the preferred course for treatment; in
particular, ertapenem, a once daily par-
enteral 1-b-methyl carbapenem antibiotic,
licensed in 2002 for the treatment of intra-
abdominal and gynaecological infec-
tions and community-acquired pneumonia
(Livermore et al., 2003). It is considered
a first-line antibiotic for complicated
community-acquired infections and, as such,
is often prescribed for the treatment of
ESBL-producing coliform infections
(Livermore et al., 2003). It has been
shown that the use of ertapenem in
K. pneumoniae can select for the loss of the
major outer-membrane protein OmpK36,
resulting in reduced accumulation of erta-
penem in the bacterial cell and subsequently
reduced susceptibility (Girlich et al., 2009).
Studies in K. pneumoniae have shown that
the loss of OmpK36 and the presence of
non-carbapenemase b-lactamases, such as
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the ESBL CTX-M-15, are sufficient to exert
resistance to ertapenem whilst causing a
concomitant reduction in susceptibility to
meropenem and imipenem (Doumith et al.,
2009; Jacoby et al., 2004). The potential for
cross-resistance is particularly worrying
because if ertapenem is administered to a
patient prior to other carbapenem treatment
for a recurring infection, porin-deficient
mutants may be inadvertently selected for,
resulting in reduced susceptibility to the
other carbapenems, which potentially can
result in therapy failure.
Carbapenems, especially the broad-spec-
trum variants, are an extremely important
part of our ability to control severe Gram-
negative infections, particularly those
caused by multidrug-resistant bacteria.
However, resistance is emerging in the form
of new b-lactamases able to migrate to
clinically important strains and confer high
levels of clinical resistance, a situation
similar to that seen with the ESBLs two
decades ago. The situation is more
complicated; some species of bacteria
(A. baumannii, K. pneumoniae, etc.) already
possess b-lactamases that can, under certain
conditions particularly with the assistance
of reduced permeability, reduce the sus-
ceptibility of the bacterium to all carbape-
nems. The alternative to carbapenem
therapy is the re-emergence of the poly-
myxins, such as colistin methanesulphate,
which are considered a last resort salvage
therapy (Li et al., 2006). The ESBLs caused
the decline of the cephalosporins; there are
now sufficient b-lactamases to do the same
to the carbapenems. Prudent therapy with
carbapenems should prolong their efficacy
and this should not be compromised by
empiric therapy with less-active drugs. The
alternative would be an increased reliance
on colistin and that would appear a poor
substitute if we allow the carbapenems to
join the large group of excellent antibiotics
that we once had to treat severe Gram-
negative infections.
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